{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:15:46Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 15.4, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094e5-8434-73e1-b972-c497128d3916\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: dixyrazine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 82.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094e5-8439-7542-9d8d-0f126de4dbd7\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: dixyrazine\nRegistry id: vr.tr.dixyrazine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:55:21+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:29+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q2759774", "registryId": "vr.tr.dixyrazine", "name": "dixyrazine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q2759774/", "model": { "registry_id": "vr.tr.dixyrazine", "name": "dixyrazine", "purpose": "Enable an agent to recognise dixyrazine, assess the identity and condition of a material containing it, and determine which handling or use decisions have sufficient evidence.", "definition": "Dixyrazine is a phenothiazine derivative used as an antipsychotic and antiemetic, with sedative effects.", "scope_statement": "This model owns the substance identity of dixyrazine under vr.tr.dixyrazine in PHY / PHY.MAT, including molecular identity, material form, quality, physicochemical behaviour and evidence governing use.", "in_scope": [ "Dixyrazine molecular identity, identifiers and structural recognition", "Free-base identity and relationships to explicitly identified salts, solvates and stereochemical forms", "Sample composition, assay, impurities and intended grade", "Physical properties, solution behaviour and stability under recorded conditions", "Substance-level biological evidence, hazards and jurisdiction-specific restrictions" ], "out_of_scope": [ "Finished medicines, brands, excipients and dosage-form performance", "Patient diagnosis, prescribing and individual treatment decisions", "Manufacturing plant design and complete synthesis procedures", "Other phenothiazines and their independent substance identities", "Supplier organisations and laboratory equipment" ], "distinguishing_features": [ "Match the complete molecular connectivity to dixyrazine, rather than accepting membership in the phenothiazine family as identification.", "Check for the phenothiazine nitrogen substituent containing a methyl-branched propyl connection to piperazine and a hydroxyethoxyethyl substituent on the other piperazine nitrogen; this test is derived from the structure in [NIST Chemistry WebBook](https://webbook.nist.gov/cgi/cbook.cgi?ID=C2470737&Units=SI).", "Cross-check the neutral substance against formula C24H33N3O2S, CAS 2470-73-7 and InChIKey MSYUMPGNGDNTIQ-UHFFFAOYSA-N; agreement supports record matching but does not authenticate a sample. [NIST Chemistry WebBook](https://webbook.nist.gov/cgi/cbook.cgi?ID=C2470737&Units=SI)", "Require counterion and stoichiometry evidence before treating a salt-labelled material as equivalent to the neutral substance.", "Distinguish a dixyrazine-containing medicinal product from dixyrazine itself by checking its complete composition and product identity." ], "characteristics": [ { "name": "Molecular identity", "kind": "category", "unit_or_values": "Structure identifier, CAS number and formula; neutral identity anchored to CAS 2470-73-7 and C24H33N3O2S", "why_it_matters": "Prevents substitution of another phenothiazine or a product name for the substance. [NIST Chemistry WebBook](https://webbook.nist.gov/cgi/cbook.cgi?ID=C2470737&Units=SI)" }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base, specified salt, specified solvate or hydrate, mixture, unresolved", "why_it_matters": "Controls applicable molecular mass, assay basis and interpretation of physical properties." }, { "name": "Stereochemical specification", "kind": "category", "unit_or_values": "Unspecified, documented racemate, characterised stereoisomer mixture, specified stereoisomer", "why_it_matters": "Prevents an unspecified structure record from being treated as evidence of a sample's stereochemical composition." }, { "name": "Dixyrazine assay", "kind": "measurement", "unit_or_values": "% mass fraction or mg/g; specify as-is, dried, salt or free-base-equivalent basis", "why_it_matters": "Makes purity and quantity comparisons meaningful across material forms." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Named impurity concentrations in mg/g or ppm; unidentified chromatographic peaks reported separately", "why_it_matters": "Determines whether a batch meets the requirements of its intended use." }, { "name": "Physical state and thermal behaviour", "kind": "state", "unit_or_values": "Observed phase at temperature and pressure; melting, transition or decomposition temperature in °C with method", "why_it_matters": "Separates observations for different forms and avoids interpreting decomposition as boiling or melting." }, { "name": "Solubility and ionisation", "kind": "measurement", "unit_or_values": "Solubility in mg/mL or mol/L with solvent, pH and temperature; pKa with method and conditions", "why_it_matters": "Supports preparation and interpretation of dixyrazine solutions without assuming all forms behave alike." }, { "name": "Storage and stability status", "kind": "state", "unit_or_values": "Within supported conditions, excursion under assessment, failed specification, unknown", "why_it_matters": "Connects storage history to evidence that the material remains usable." }, { "name": "Biological evidence context", "kind": "relation", "unit_or_values": "Linked study, tested material, target or endpoint, test system, concentration or exposure and result", "why_it_matters": "Prevents a broad pharmacological label from replacing evidence about dixyrazine in a particular setting." }, { "name": "Hazard and regulatory applicability", "kind": "relation", "unit_or_values": "Linked SDS or authority record with material form, jurisdiction, date, classification and restrictions", "why_it_matters": "Makes handling and use decisions depend on applicable evidence rather than assumptions about related drugs." } ], "affordances": [ "Reconcile a candidate substance record with dixyrazine using structure and identifier evidence.", "Assess whether a batch has adequate identity, assay and impurity evidence for a stated laboratory purpose.", "Convert a documented salt quantity to dixyrazine free-base equivalent when stoichiometry, hydration and assay are known.", "Compare physical-property measurements only after matching material form and experimental conditions.", "Flag unsupported storage, exposure or use decisions for review.", "Link a dixyrazine-containing product or biological study to the substance while preserving its separate context." ], "agent_conduct": { "may": [ "Explain dixyrazine as a phenothiazine antipsychotic and antiemetic and where it is authorized, from official sources.", "Report warnings and side effects from official labelling." ], "must_not": [ "Recommend, dose or adjust dixyrazine for a specific person.", "Suggest giving it to someone without their knowledge or consent.", "Advise combining it with alcohol or other sedatives.", "Stigmatize people who take antipsychotic medicines." ], "requires_human": [ "Starting, stopping or changing antipsychotic or antiemetic treatment for a patient." ] }, "ethics": { "considerations": [ "Sedating drugs can be misused to control people against their will.", "Patients with mental illness deserve dignity and informed consent." ], "affected_parties": [ "Patients", "Families and carers", "Prescribers" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and pack details rather than by appearance alone." ], "failure_modes_and_hazards": [ "Sedation and impaired driving.", "Movement disorders.", "Interactions with alcohol and sedatives." ], "what_it_is_for": [ "Dixyrazine is encountered in pharmaceutical literature and medicinal preparations associated with antipsychotic, antiemetic and sedative uses.", "Laboratory and pharmaceutical records use its chemical identity to distinguish the active substance from salts, impurities and finished formulations." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification, maintained by the WHO Collaborating Centre for Drug Statistics Methodology, classifies dixyrazine as N05AB01 within phenothiazines with a piperazine structure." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q2759774: dixyrazine", "url": "https://www.wikidata.org/wiki/Q2759774", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Dixyrazine", "url": "https://en.wikipedia.org/wiki/Dixyrazine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "dixyrazine-identity", "name": "Dixyrazine identity", "description": "Resolve exactly which molecular entity the registry name denotes.", "rationale": "Phenothiazine membership and medicinal names are insufficient to identify dixyrazine.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Use complete connectivity and authoritative identifiers to establish identity.", "findings": [ { "id": "structure-identifier-agreement", "name": "Structure and identifier agreement", "description": "Require evidence that names, identifiers and molecular structure refer to the same dixyrazine entity.", "questions": [ { "text": "Does the candidate structure reproduce dixyrazine's phenothiazine, branched propyl, substituted piperazine and hydroxyethoxyethyl connectivity?", "kind": "definition", "id": "structure-identifier-agreement-q01" }, { "text": "Which read authority records support the CAS, PubChem and structure-identifier mappings, and do any mappings conflict?", "kind": "provenance", "id": "structure-identifier-agreement-q02" } ] } ] }, { "id": "form-and-name-boundaries", "name": "Form and name boundaries", "description": "Separate the neutral identity from form-specific and product-specific assertions.", "findings": [ { "id": "salt-stereochemistry-and-aliases", "name": "Salt, stereochemistry and aliases", "description": "Treat counterions, stereochemical composition and commercial names as claims requiring explicit qualification.", "questions": [ { "text": "Does each encountered name denote neutral dixyrazine, a specified salt or a finished medicinal product?", "kind": "boundary", "id": "salt-stereochemistry-and-aliases-q01" }, { "text": "What evidence establishes the sample's stereochemical composition rather than merely leaving stereochemistry unspecified?", "kind": "measurement", "id": "salt-stereochemistry-and-aliases-q02" } ] } ] } ] }, { "id": "dixyrazine-material-quality", "name": "Dixyrazine material quality", "description": "Determine what a particular dixyrazine batch contains and whether its quality supports the intended use.", "rationale": "A matching substance name does not establish usable purity or comparable quantities.", "layers": [ { "id": "assay-and-equivalence", "name": "Assay and equivalence", "description": "Establish dixyrazine content with an explicit chemical and mass basis.", "findings": [ { "id": "content-basis", "name": "Content basis", "description": "Keep dixyrazine assay distinct from salt mass, water content and chromatographic area percentage.", "questions": [ { "text": "What method measures dixyrazine content, and is the result expressed as supplied material or free-base equivalent?", "kind": "measurement", "id": "content-basis-q01" }, { "text": "Are counterion stoichiometry, water or solvent content and assay known well enough to calculate a defensible free-base-equivalent quantity?", "kind": "action", "id": "content-basis-q02" } ] } ] }, { "id": "identity-and-impurity-evidence", "name": "Identity and impurity evidence", "description": "Assess analytical identification and contaminants for the specific batch.", "findings": [ { "id": "batch-fitness", "name": "Batch fitness", "description": "Connect analytical evidence and impurity limits to the intended application.", "questions": [ { "text": "Which orthogonal analytical results distinguish dixyrazine from related phenothiazines, synthesis impurities and degradation products?", "kind": "measurement", "id": "batch-fitness-q01" }, { "text": "Which documented specification governs acceptance of this batch, and does its evidence support that grade?", "kind": "action", "id": "batch-fitness-q02" } ] } ] } ] }, { "id": "dixyrazine-physical-behaviour", "name": "Dixyrazine physical behaviour", "description": "Characterise the material under conditions relevant to storage, measurement and solution preparation.", "rationale": "Properties cannot safely be transferred between neutral dixyrazine, salts and mixtures.", "layers": [ { "id": "phase-and-thermal-properties", "name": "Phase and thermal properties", "description": "Associate observed physical properties with the actual tested material form.", "findings": [ { "id": "form-specific-constants", "name": "Form-specific constants", "description": "Require experimental context before using a reported physical constant.", "questions": [ { "text": "Which dixyrazine form, purity, temperature and pressure underlie each reported phase, density or melting-point observation?", "kind": "measurement", "id": "form-specific-constants-q01" }, { "text": "Does a reported thermal endpoint represent melting, solvent loss or decomposition, and is any boiling-point value measured or predicted?", "kind": "provenance", "id": "form-specific-constants-q02" } ] } ] }, { "id": "solution-and-storage-behaviour", "name": "Solution and storage behaviour", "description": "Resolve dissolution, ionisation and chemical stability without assuming numerical values.", "findings": [ { "id": "preparation-and-stability-window", "name": "Preparation and stability window", "description": "Determine the supported conditions for keeping dixyrazine in a usable material or solution state.", "questions": [ { "text": "What measured solubility and ionisation data apply to the selected dixyrazine form, solvent, pH and temperature?", "kind": "measurement", "id": "preparation-and-stability-window-q01" }, { "text": "What studies establish acceptable exposure to light, oxygen, moisture and temperature, including stability after dissolution?", "kind": "provenance", "id": "preparation-and-stability-window-q02" }, { "text": "Which observed changes or storage excursions require retesting or rejection of the material?", "kind": "action", "id": "preparation-and-stability-window-q03" } ] } ] } ] }, { "id": "dixyrazine-biological-evidence", "name": "Dixyrazine biological evidence", "description": "Organise compound-specific evidence for biological activity and its limits.", "rationale": "An agent must distinguish observed dixyrazine effects from phenothiazine-class expectations and treatment decisions.", "layers": [ { "id": "activity-and-test-context", "name": "Activity and test context", "description": "Attach activity claims to the tested substance and experimental system.", "findings": [ { "id": "compound-specific-activity", "name": "Compound-specific activity", "description": "Resolve biological targets and functional effects through evidence specific to dixyrazine.", "questions": [ { "text": "Which primary studies directly establish dixyrazine's molecular targets or functional effects rather than infer them from other phenothiazines?", "kind": "provenance", "id": "compound-specific-activity-q01" }, { "text": "What test system, material form, concentration, endpoint and uncertainty accompany each activity result?", "kind": "measurement", "id": "compound-specific-activity-q02" } ] } ] }, { "id": "exposure-and-interpretation", "name": "Exposure and interpretation", "description": "Separate parent-substance findings from metabolite effects and clinical-product claims.", "findings": [ { "id": "evidence-transfer-limits", "name": "Evidence transfer limits", "description": "Make the limits of biological interpretation explicit.", "questions": [ { "text": "Does each exposure or effect measurement concern unchanged dixyrazine, a metabolite or an unresolved combined signal?", "kind": "boundary", "id": "evidence-transfer-limits-q01" }, { "text": "Which evidence supports connecting a laboratory result to a proposed use, and which decisions belong to a medicinal-product or clinical model?", "kind": "action", "id": "evidence-transfer-limits-q02" } ] } ] } ] }, { "id": "dixyrazine-handling-and-status", "name": "Dixyrazine handling and status", "description": "Determine applicable handling controls and substance-level legal or use constraints.", "rationale": "Chemical identification and biological activity do not by themselves establish safe handling or permitted use.", "layers": [ { "id": "hazards-and-exposure-controls", "name": "Hazards and exposure controls", "description": "Use dixyrazine-specific evidence applicable to the supplied material.", "findings": [ { "id": "applicable-hazard-evidence", "name": "Applicable hazard evidence", "description": "Record supported classifications and controls while preserving missing information.", "questions": [ { "text": "Which current SDS or authoritative assessment covers this dixyrazine form and supports its GHS classification?", "kind": "provenance", "id": "applicable-hazard-evidence-q01" }, { "text": "Are substance-specific occupational exposure limits available, and which jurisdiction and exposure period do they cover?", "kind": "measurement", "id": "applicable-hazard-evidence-q02" }, { "text": "Which documented controls govern weighing, solution handling, spills and disposal for the planned operation?", "kind": "action", "id": "applicable-hazard-evidence-q03" } ] } ] }, { "id": "jurisdiction-and-use-eligibility", "name": "Jurisdiction and use eligibility", "description": "Separate substance registration from medicinal-product authorisation and batch suitability.", "findings": [ { "id": "dated-status-and-permitted-purpose", "name": "Dated status and permitted purpose", "description": "Anchor use decisions to the relevant entity, territory, date and evidence.", "questions": [ { "text": "Which verified regulatory identifiers, including any EC number, apply specifically to dixyrazine or the documented material form?", "kind": "provenance", "id": "dated-status-and-permitted-purpose-q01" }, { "text": "Does a cited authorisation concern the substance, a particular product or a historical market status?", "kind": "boundary", "id": "dated-status-and-permitted-purpose-q02" }, { "text": "What evidence is still required before this batch can be accepted for the proposed research, analytical or pharmaceutical purpose?", "kind": "action", "id": "dated-status-and-permitted-purpose-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Confirm exact chemical identifiers, molecular formula, salt forms and physical constants before adding them.", "Verify current authorization, availability and approved indications by jurisdiction; the uses listed do not establish present approval." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of dixyrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "dixyrazine", "note": "Names the active substance rather than a particular medicinal product." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of dixyrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historical medicinal use as an antipsychotic.", "Medicinal use to control nausea and vomiting." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of dixyrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Sedation and impaired alertness.", "Orthostatic hypotension.", "Extrapyramidal adverse effects, including drug-induced movement disorders.", "Potential for additive sedation when combined with alcohol or other central nervous system depressants." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of dixyrazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "phenothiazine", "difference": "Phenothiazine is the parent chemical scaffold; dixyrazine is a specific substituted derivative with medicinal activity." }, { "name": "chlorpromazine", "difference": "Both are phenothiazine drugs, but they are distinct active substances with different substituents and pharmacological profiles." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of dixyrazine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which salts and stereochemical specifications are authoritatively documented for dixyrazine, and how should their identifiers relate to this unsplit registry entry?", "What experimentally measured phase, melting or decomposition, solubility and pKa data exist for clearly identified dixyrazine forms?", "Which validated analytical methods, reference standards, impurity limits and stability studies support meaningful batch acceptance?", "Which primary studies establish dixyrazine-specific pharmacology, metabolism and toxicology, and where are existing claims only class-based inference?", "What current EC identity, GHS classifications, exposure limits and jurisdiction-specific restrictions are verifiable for the substance and its supplied forms?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 15, "questions": 28 } }